TY - JOUR
T1 - Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction
AU - Vesell, Elliot S.
AU - Shapiro, Jay R.
AU - Passananti, G. Thomas
AU - Jorgensen, Hildegarde
AU - Shively, Carol A.
PY - 1975/1
Y1 - 1975/1
N2 - In normal, nonmedicated volunteers and in patients with thyroid disorders the plasma half-lives of antipyrine, propylthiouracil, and methimazole were determined after single oral, doses. The plasma half-lives ± S.D. of antipyrine, propylthiouracil, and methimazole were 11.9 ± 1.4 hr, 6.7 ± 1.0 hr, and 9.3 ± 1.4 hr, respectively, in normal volunteers, but were shortened to 7.7 ± 1.2 hr, 4.3 ± 0.7 hr, and 6.9 ± 0.6 hr, respectively, in hyperthyroid patients, In hypothyroid patients the plasma half-lives of these drugs were prolonged to 26.4 ± 4.0 hr, 24.7 ± 34.5 hr, and 13.6 ± 4.8 hr, respectively. Return to the euthyroid state restored plasma half-lives to or toward normal. Alterations in plasma drug half-lives during thyroid dysfunction appear to result mainly from accelerated hepatic microsomal drug metabolism in hyperthyroidism and retarded drug biotransformation during hypothyroidism.
AB - In normal, nonmedicated volunteers and in patients with thyroid disorders the plasma half-lives of antipyrine, propylthiouracil, and methimazole were determined after single oral, doses. The plasma half-lives ± S.D. of antipyrine, propylthiouracil, and methimazole were 11.9 ± 1.4 hr, 6.7 ± 1.0 hr, and 9.3 ± 1.4 hr, respectively, in normal volunteers, but were shortened to 7.7 ± 1.2 hr, 4.3 ± 0.7 hr, and 6.9 ± 0.6 hr, respectively, in hyperthyroid patients, In hypothyroid patients the plasma half-lives of these drugs were prolonged to 26.4 ± 4.0 hr, 24.7 ± 34.5 hr, and 13.6 ± 4.8 hr, respectively. Return to the euthyroid state restored plasma half-lives to or toward normal. Alterations in plasma drug half-lives during thyroid dysfunction appear to result mainly from accelerated hepatic microsomal drug metabolism in hyperthyroidism and retarded drug biotransformation during hypothyroidism.
UR - http://www.scopus.com/inward/record.url?scp=0016435331&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016435331&partnerID=8YFLogxK
U2 - 10.1002/cpt197517148
DO - 10.1002/cpt197517148
M3 - Article
C2 - 1122669
AN - SCOPUS:0016435331
SN - 0009-9236
VL - 17
SP - 48
EP - 56
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 1
ER -